OverviewSuggest Edit

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics holds the exclusive right to develop and commercialize tirasemtiv throughout the world. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights.
TypePublic
Founded1997
HQSouth San Francisco, CA, US
Websitecytokinetics.com
Employee Ratings3.6
Overall CultureC

Latest Updates

Employees (est.) (Dec 2019)156(+20%)
Revenue (FY, 2019)$26.9 M(-14%)
Share Price (Jan 2021)$21.5
Cybersecurity ratingCMore

Key People/Management at Cytokinetics

Robert I. Blum

Robert I. Blum

President, Chief Executive Officer & Director
Durga Bobba

Durga Bobba

VP, Global Franchise General Manager, Cardiovascular
Daniel R. Casper

Daniel R. Casper

VP, Information Technology
Bonnie A. Charpentier

Bonnie A. Charpentier

SVP, Regulatory Affairs and Compliance
David W. Cragg

David W. Cragg

Chief Human Resources and Administration Officer
Erin Donnelly

Erin Donnelly

VP, Portfolio & Project Management
Show more

Cytokinetics Office Locations

Cytokinetics has an office in South San Francisco
South San Francisco, CA, US (HQ)
280 E Grand Ave
Show all (1)

Cytokinetics Financials and Metrics

Cytokinetics Revenue

Cytokinetics's revenue was reported to be $26.87 m in FY, 2019
USD

Revenue (Q3, 2020)

41.7m

Net income (Q3, 2020)

(3.2m)

EBIT (Q3, 2020)

5.2m

Market capitalization (8-Jan-2021)

1.5b

Closing stock price (8-Jan-2021)

21.5

Cash (30-Sept-2020)

200.8m

EV

1.4b
Cytokinetics's current market capitalization is $1.5 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

4.0m7.6m30.6m46.9m28.7m106.4m13.4m31.5m26.9m

Revenue growth, %

53%(39%)271%

General and administrative expense

13.6m12.4m15.1m17.3m19.7m27.8m36.5m31.3m39.6m

R&D expense

37.2m35.6m49.5m44.4m46.4m59.9m90.3m89.1m86.1m
Quarterly
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

18.8m14.9m20.2m20.2m65.1m66.9m125.2m42.3m36.4m

Accounts Receivable

1.1m2.2m5.2m

Prepaid Expenses

2.1m2.4m1.6m1.3m1.7m4.3m2.2m3.5m

Inventories

Quarterly
USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

Cytokinetics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

72/100

SecurityScorecard logo

Cytokinetics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Cytokinetics Online and Social Media Presence

Embed Graph

Cytokinetics Company Culture

  • Overall Culture

    C

    69/100

  • CEO Rating

    A-

    80/100

  • Compensation

    A+

    97/100

Learn more on Comparably

Cytokinetics News and Updates

Cytokinetics Regains European Rights to Omecamtiv Mecarbil

Company is Planning Regulatory Interactions in 2021 to Discuss Results of GALACTIC-HF and Expects to Evaluate Strategic Options for Co-Commercialization and Licensing Company is Planning Regulatory Interactions in 2021 to Discuss Results of GALACTIC-HF and Expects to Evaluate Strategic Options for C…

Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MND

Additional Data from FORTITUDE-ALS Support Rationale and Design for COURAGE-ALS, A Planned Phase 3 Clinical Trial of Reldesemtiv in Patients with ALS Additional Data from FORTITUDE-ALS Support Rationale and Design for COURAGE-ALS, A Planned Phase 3 Clinical Trial of Reldesemtiv in Patients with ALS

Cytokinetics Announces Progression of REDWOOD-HCM to Cohort 2

Interim Analysis of Data from Cohort 1 Demonstrate Substantial Effects of CK-274 to Reduce LVOT Gradient in Patients with Obstructive Hypertrophic Cardiomyopathy with No Dose Interruptions Due to Left Ventricular Ejection Fraction Below 50% Interim Analysis of Data from Cohort 1 Demonstrate Substant…

Cytokinetics Announces Three Presentations at the International Symposium on ALS/MND

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the 31st International Symposium on ALS/MND taking place online from December 9 – December 11, 2020.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2020 it granted stock options to purchase an aggregate of 62,850 shares of common stock to six new employees whose employment commenced in November 2020 as …

Cytokinetics Announces Additional Results From GALACTIC-HF to be Presented at the 17th Global Cardiovascular Clinical Trialists Forum

Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting
Show more

Cytokinetics Blogs

Cytokinetics Announces First Patient Dosed in Cohort 2 of REDWOOD-HCM

Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals SOUTH SAN FRANCISCO, Calif. , Jan. 13, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced that the first patient has been dosed in Cohort 2 of REDWOOD-HCM ( R andomized E valuation of D osing W ith

H.C. Wainwright BioConnect 2021 Virtual Conference

H.C. Wainwright BioConnect 2021 Virtual Conference marco.guevara@… Wed, 01/06/2021 - 19:53 H.C. Wainwright BioConnect 2021 Virtual Conference Display "add to calendar" true Event Type Other Corporate Click here for webcast …

Cytokinetics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

SOUTH SAN FRANCISCO, Calif. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference

Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the 17th Global Cardiovascular Clinical Trialists

Supplemental Analyses of Primary Composite Endpoint Further Demonstrate Effect of Omecamtiv Mecarbil In Patie nts with Lower Ejection Fraction SOUTH SAN FRANCISCO, Calif. , Dec. 07, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from

Cytokinetics Investor Event

Cytokinetics Investor Event ronryan.teano@… Sun, 11/22/2020 - 21:27 Cytokinetics Investor Event Display "add to calendar" true Event Type Other Corporate Click here for webcast Nov 23, 2…

Cytokinetics Announces Results From GALACTIC-HF Presented at Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions and Published in the New England Journal of Medicine

Trial Met Primary Composite Endpoint of Reduction in Heart Failure Events or Cardiovascular Death; Did Not Meet Secondary Endpoints Including Reduction in Cardiovascular Death The Global Toll of Heart Failure, A Time for Action Effect of Omecamtiv Mecarbil Consistent Across Most Prespecified
Show more

Cytokinetics Frequently Asked Questions

  • When was Cytokinetics founded?

    Cytokinetics was founded in 1997.

  • Who are Cytokinetics key executives?

    Cytokinetics's key executives are Robert I. Blum, Durga Bobba and Daniel R. Casper.

  • How many employees does Cytokinetics have?

    Cytokinetics has 156 employees.

  • What is Cytokinetics revenue?

    Latest Cytokinetics annual revenue is $26.9 m.

  • What is Cytokinetics revenue per employee?

    Latest Cytokinetics revenue per employee is $172.2 k.

  • Who are Cytokinetics competitors?

    Competitors of Cytokinetics include Consort Medical, Jazz Pharmaceuticals and Bausch Health Companies.

  • Where is Cytokinetics headquarters?

    Cytokinetics headquarters is located at 280 E Grand Ave, South San Francisco.

  • Where are Cytokinetics offices?

    Cytokinetics has an office in South San Francisco.

  • How many offices does Cytokinetics have?

    Cytokinetics has 1 office.